Technical Analysis for EXEL - Exelixis, Inc.

Grade Last Price % Change Price Change
grade A 18.0 -3.38% -0.63
EXEL closed up 5.79 percent on Wednesday, April 8, 2020, on 1.15 times normal volume. The stock rose above its 50 day moving average, improving its intermediate-term outlook by crossing above that important trendline. The stock crossed above its 200 day moving average, improving its long-term outlook by crossing above that critical trendline. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.
Earnings due: Apr 29
*** please verify all earnings dates ***

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Flat Up
Historical EXEL trend table...

Date Alert Name Type % Chg
Crossed Above 200 DMA Bullish -3.38%
Crossed Above 50 DMA Bullish -3.38%
180 Bullish Setup Bullish Swing Setup -3.38%
Stochastic Reached Overbought Strength -3.38%
Overbought Stochastic Strength -3.38%
Upper Bollinger Band Touch Strength -3.38%
200 DMA Resistance Bearish 2.21%
50 DMA Resistance Bearish 2.21%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 2.21%
Upper Bollinger Band Touch Strength 2.21%

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile

Exelixis, Inc., a biotechnology company, engages in developing small molecule therapies for the treatment of cancer in the United States. It focuses on developing and commercializing COMETRIQ (cabozantinib), an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive, metastatic medullary thyroid cancer. COMETRIQ is also involved in various other cancer indications, including two ongoing Phase III pivotal trials in metastatic castration-resistant prostate cancer; and two additional Phase III pivotal trials in metastatic hepatocellular cancer and metastatic renal cell cancer. In addition, the company has a portfolio of other novel compounds that address serious unmet medical needs. Exelixis, Inc. has collaborations with Bristol-Myers Squibb Company, Sanofi, Genentech, Inc., GlaxoSmithKline, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Chemistry Biotechnology Cancer Treatment Of Cancer Cyclopropanes Sanofi Tyrosine Kinase Inhibitors Protein Kinase Inhibitor Genentech Small Molecule Therapies Metastatic Castration Resistant Prostate Cancer

Is EXEL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 23.93
52 Week Low 13.67
Average Volume 3,670,783
200-Day Moving Average 18.51
50-Day Moving Average 17.99
20-Day Moving Average 16.31
10-Day Moving Average 17.30
Average True Range 1.17
ADX 17.63
+DI 26.12
-DI 16.15
Chandelier Exit (Long, 3 ATRs ) 15.18
Chandelier Exit (Short, 3 ATRs ) 17.17
Upper Bollinger Band 18.67
Lower Bollinger Band 13.96
Percent B (%b) 0.99
BandWidth 28.86
MACD Line -0.03
MACD Signal Line -0.36
MACD Histogram 0.3292
Fundamentals Value
Market Cap 5.48 Billion
Num Shares 294 Million
EPS 0.20
Price-to-Earnings (P/E) Ratio 93.15
Price-to-Sales 23.83
Price-to-Book 51.23
PEG Ratio 2.01
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 20.16
Resistance 3 (R3) 20.01 19.34 19.91
Resistance 2 (R2) 19.34 18.95 19.42 19.82
Resistance 1 (R1) 18.99 18.71 19.17 19.14 19.73
Pivot Point 18.32 18.32 18.41 18.40 18.32
Support 1 (S1) 17.97 17.93 18.15 18.12 17.53
Support 2 (S2) 17.30 17.69 17.38 17.44
Support 3 (S3) 16.95 17.30 17.36
Support 4 (S4) 17.10